Developing the next generation bacterial cancer therapy
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.
Company Details
- Employees
- 27
- Founded
- -
- Address
- C/o Biozentrum, Universität Basel, Klingelbergstr. 50/70,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.t3pharma.com
- HQ
- Basel, BS
T3 Pharmaceuticals Ag Questions
T3 Pharmaceuticals Ag's website is http://www.t3pharma.com
T3 Pharmaceuticals Ag's LinkedIn profile is https://ch.linkedin.com/company/t3pharma
T3 Pharmaceuticals Ag has
27 employees.
View email and phone details for 27
employees at T3 Pharmaceuticals Ag.
T3 Pharmaceuticals Ag's industry is
Biotechnology Research
T3 Pharmaceuticals Ag's top competitors are
Versameb Ag,
Boehringer Ingelheim,
Switzerland Innovation Park Basel Area,
Amal Therapeutics,
Araris Biotech Ag,
Aurealis Therapeutics,
Cellestia Biotech,
Alentis Therapeutics,
Synendos Therapeutics Ag,
Nbe-Therapeutics Ag.
T3 Pharmaceuticals Ag's categories are Biotechnology Research
T3 Pharmaceuticals Ag's founding year is 2015
